Lohja as, Finland

Tuula Koskelainen



 

Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 7(Granted Patents)


Location History:

  • Lohja as, FI (2008 - 2009)
  • Lohja, FI (2016)

Company Filing History:


Years Active: 2008-2016

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Tuula Koskelainen: Innovator in Pharmaceutical Compounds

Introduction

Tuula Koskelainen is a notable inventor based in Lohja, Finland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that exhibit alpha2 agonistic activity. With a total of three patents to her name, her work has implications for therapeutic applications.

Latest Patents

Among her latest patents, one focuses on alpha2 adrenoceptor agonists, specifically compounds of formula (I). These compounds, wherein X and R-R are defined in the claims, exhibit alpha2 agonistic activity, making them useful as alpha2 agonists, especially as alpha2A agonists. Additionally, she has developed pyridine derivatives that are useful for inhibiting the sodium/calcium exchange system. These therapeutically active compounds, defined in formulas (I) and (II), are potent inhibitors of the Na/Ca exchange mechanism.

Career Highlights

Tuula Koskelainen has established herself as a key figure in her field through her innovative research and development efforts. Her work at Orion Corporation has allowed her to explore and create new pharmaceutical solutions that address critical health issues.

Collaborations

Tuula has collaborated with several professionals in her field, including Leena Otsomaa and Arto J Karjalainen. These collaborations have further enhanced her research and contributed to the success of her projects.

Conclusion

Tuula Koskelainen's contributions to pharmaceutical innovations demonstrate her expertise and commitment to advancing medical science. Her patents reflect her dedication to developing effective therapeutic compounds that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…